A Phase I/II Dose Escalation Trial of HDAC Inhibitor Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma

Trial Profile

A Phase I/II Dose Escalation Trial of HDAC Inhibitor Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 May 2016

At a glance

  • Drugs Tefinostat (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Mar 2016 Planned End Date changed from 31 Jan 2016 to 31 May 2016 as reported by United Kingdom Clinical Research Network.
    • 10 Dec 2015 Planned End Date changed from 31 Jul 2015 to 31 Jan 2016 according to United Kingdom Clinical Research Network record.
    • 05 Mar 2015 Accrual to date is 21% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top